- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07937891
The PRECISE-DIET Trial
Precision Nutrition Versus Standard Dietary Care: Effect of Personalised Nutrition Guidance Based on Continuous Glucose Monitoring in Type 2 Diabetes - The PRECISE-DIET Trial
People with type 2 diabetes receive standard dietary advice to improve glycaemic control. However, blood glucose responses to the same foods can vary considerably between individuals. This randomised controlled trial aims to investigate whether personalised carbohydrate recommendations guided by continuous glucose monitoring (CGM) improve glycaemic control (HbA1c) compared with standard dietary care.
A total of 130 adults with type 2 diabetes will be randomly assigned to one of two groups. The study will include a 6-month intervention period followed by a 6-month follow-up period. The intervention group will receive dietitian-led personalised carbohydrate recommendations informed by CGM data, supplemented by group-based education in carbohydrate counting. The control group will receive standard individual dietary counselling provided by a dietitian without the use of CGM.
The primary outcome is the between-group difference in change in HbA1c from baseline to 6 months.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Zandra Overgaard Pedersen, MSc. Health Science
- Telefonnummer: 24456114
- E-post: zandra.overgaard.pedersen@regionh.dk
Studera Kontakt Backup
- Namn: Bettina Ewers, PhD
- Telefonnummer: 30912997
- E-post: bettina.ewers@regionh.dk
Studieorter
-
-
-
Herlev, Danmark, 2730
- Steno Diabetes Center Copenhagen
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- T2D
- Diabetes duration of ≥12 months
- Age ≥18 years
- HbA1c ≥58 mmol/mol
- Attending the SDCC outpatient clinic
- Provided voluntary signed informed consent
Exclusion Criteria:
- Inability to understand the study information
- Medical complications that prevent lowering HbA1c to below 58 mmol/mol
- Use of insulin therapy
- Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion
- Systematic use of corticosteroids
- Using or requiring a specialised diet (e.g., protein restriction in kidney disease)
- Circumstances that affect HbA1c (e.g., liver disease and anaemia)
- Known or suspected drug or alcohol abuse
- Pregnancy or breastfeeding or plans of pregnancy within the study period
- Participation in other clinical trials
- Individuals with a BMI of <27 kg/m²
- Initiation of GLP-1 receptor agonist or SGLT inhibitor therapy within the previous 3 months
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Personalised dietary intervention
CGM-supported personalised carbohydrate recommendations |
Participants will receive structured, personalised dietary recommendations supported by continuous glucose monitoring (CGM). Initial carbohydrate recommendations will be based on approximately 35% of total energy intake and translated into individual targets expressed as grams of carbohydrate per day and per meal. These targets will be adjusted throughout the intervention based on individual needs and glycaemic responses rather than prescribed as fixed amounts. CGM data will be used to assess individual postprandial glucose responses and guide adjustments to carbohydrate intake and its distribution throughout the day. The intervention will also include education in basic carbohydrate counting and dietitian-led counselling to support the implementation and maintenance of dietary changes. |
|
Aktiv komparator: Standard dietary counselling
Standard dietary counselling for type 2 diabetes |
Participants will receive standard dietary counselling for type 2 diabetes based on current dietary recommendations, without CGM-guided personalisation of carbohydrate intake. The counselling will include one initial 60-minute individual consultation with a dietitian, followed by two 30-minute follow-up consultations. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in HbA1c
Tidsram: Baseline to 6 months
|
Between-group difference in change in HbA1c (mmol/mol) from baseline to 6 months |
Baseline to 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in HbA1c at 12 months
Tidsram: Baseline to 12 weeks and 12 months
|
Between-group difference in HbA1c change (mmol/mol) |
Baseline to 12 weeks and 12 months
|
|
Time in range (TIR)
Tidsram: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose 3.9-10.0 mmol/L |
Baseline, 6 and 12 months
|
|
Time above range (TAR)
Tidsram: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose >10.0 mmol/L |
Baseline, 6 and 12 months
|
|
Time below range (TBR)
Tidsram: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose <3.9 mmol/L |
Baseline, 6 and 12 months
|
|
Estimated HbA1c
Tidsram: Baseline, 6 and 12 months
|
HbA1c estimated from CGM data (mmol/mol) |
Baseline, 6 and 12 months
|
|
Change in glycaemic variability
Tidsram: Baseline, 6 and 12 months
|
Coefficient of variation (%) derived from CGM |
Baseline, 6 and 12 months
|
|
Body mass index (BMI)
Tidsram: Baseline, 6 and 12 months
|
kg/m² |
Baseline, 6 and 12 months
|
|
Waist and hip circumference
Tidsram: Baseline, 6 and 12 months
|
cm |
Baseline, 6 and 12 months
|
|
Blood pressure
Tidsram: Baseline, 6 and 12 months
|
Systolic and diastolic (mmHg) |
Baseline, 6 and 12 months
|
|
plasma glucose
Tidsram: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Plasma insulin
Tidsram: Baseline, 6 and 12 months
|
pmol/L |
Baseline, 6 and 12 months
|
|
C-peptide
Tidsram: Baseline, 6 and 12 months
|
pmol/L |
Baseline, 6 and 12 months
|
|
Total cholesterol
Tidsram: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
LDL cholesterol
Tidsram: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
HDL cholesterol
Tidsram: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Triglycerides
Tidsram: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Diabetes distress (questionnaire)
Tidsram: Baseline, 6 and 12 months
|
Problem Areas in Diabetes (PAID) score |
Baseline, 6 and 12 months
|
|
Treatment satisfaction (questionnaire)
Tidsram: Baseline, 6 and 12 months
|
Diabetes Treatment Satisfaction Questionnaire (DTSQ) score |
Baseline, 6 and 12 months
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in glucose-lowering medication
Tidsram: Baseline, 6 and 12 months
|
Changes in type and dose of glucose-lowering medication |
Baseline, 6 and 12 months
|
|
Personality traits (questionnaire)
Tidsram: Baseline
|
Big Five Inventory (BFI-44) scores |
Baseline
|
|
Dietary intake
Tidsram: Baseline and 6 months
|
Total energy intake and macronutrient composition from a 3-day food record |
Baseline and 6 months
|
|
Physical activity
Tidsram: Baseline and 6 months
|
Physical activity level measured with an AX3 accelerometer worn for 7 days |
Baseline and 6 months
|
|
Carbohydrate estimation ability (questionnaire)
Tidsram: Baseline, 6 and 12 months
|
Accuracy of participants' carbohydrate estimates |
Baseline, 6 and 12 months
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- H-26063596
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .